Bruker (NASDAQ:BRKR) vs. 10x Genomics (NASDAQ:TXG) Critical Review

Bruker (NASDAQ:BRKR) and 10x Genomics (NASDAQ:TXG) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Bruker and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bruker	-3.82%	13.76%	5.47%
10x Genomics	-10.84%	-8.19%	-6.46%

Earnings & Valuation

This table compares Bruker and 10x Genomics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44 billion	2.77	-$8.60 million	($1.10)	-56.74
10x Genomics	$618.58 million	13.07	-$43.54 million	($0.52)	-119.33

Bruker has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.5% of Bruker shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Bruker and 10x Genomics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	1	6	5	2	2.57
10x Genomics	1	12	5	0	2.22

Bruker presently has a consensus price target of $60.57, suggesting a potential downside of 2.95%. 10x Genomics has a consensus price target of $68.40, suggesting a potential upside of 10.23%. Given 10x Genomics’ higher possible upside, analysts clearly believe 10x Genomics is more favorable than Bruker.

Risk and Volatility

Bruker has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Summary

Bruker beats 10x Genomics on 9 of the 14 factors compared between the two stocks.

About Bruker

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

About 10x Genomics

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.